viernes, 27 de marzo de 2015

CDC Hepatitis Updates - HCV Testing Makes Public Health Sense

CDC Hepatitis Updates - HCV Testing Makes Public Health Sense

Centers for Disease Control and Prevention



Viral Hepatitis Updates from CDC  

HCV Testing Makes Public Health Sense
In response to Is widespread screening for hepatitis C justified?, Drs. Jonathan Mermin and John W. Ward of CDC wanted to set the record straight on a number of key points including “the CDC and USPSTF recommendations for one-time testing of persons born during 1945-1965 are based on sound evidence that HCV testing linked to care is beneficial for patients, cost effective, and with the potential of averting over 120,000 deaths from HCV.”http://www.bmj.com/content/350/bmj.g7809/rr-11 


WHO issues its first hepatitis B treatment guidelines
WHO issued its first-ever guidance for the treatment of chronic hepatitis B. Worldwide, some 240 million people have chronic hepatitis B virus with the highest rates of infection in Africa and Asia. People with chronic hepatitis B infection are at increased risk of dying from cirrhosis and liver cancer. Key recommendations include: the use of a few simple non-invasive tests to assess the stage of liver disease to help identify who needs treatment; prioritizing treatment for those with cirrhosis - the most advanced stage of liver disease; the use of two safe and highly effective medicines for the treatment of chronic hepatitis B; and regular monitoring using simple tests for early detection of liver cancer, to assess whether treatment is working, and if treatment can be stopped.http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1


New
 Hepatitis C & Injection Drug Use Fact Sheet
CDC has developed a fact sheet on Hepatitis C and injection drug use. The fact sheet includes an overview of hepatitis C including symptoms, testing, transmission, prevention, treatment, and reinfection. 
http://www.cdc.gov/hepatitis/HCV/PDFs/FactSheet-PWID.pdf


FDA Safety Alert
Hepatitis C Treatments Containing Sofosbuvir in Combination With Another Direct Acting Antiviral Drug: Drug Safety Communication - Serious Slowing of Heart Rate When Used With Antiarrhythmic Drug Amiodaronehttp://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439662.htm

No hay comentarios:

Publicar un comentario